Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis

被引:109
作者
Schiff, RL
Kahn, SR
Shrier, I
Strulovitch, C
Hammouda, W
Cohen, E
Zukor, D
机构
[1] Sir Mortimer B Davis Jewish Hosp, Ctr Clin Epidemiol & Commun Studies, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Dept Med, Montreal, PQ H3A 2T5, Canada
[3] Sir Mortimer B Davis Jewish Hosp, Div Orthoped Surg, Montreal, PQ H3T 1E2, Canada
[4] Sir Mortimer B Davis Jewish Hosp, Div Hematol, Montreal, PQ H3T 1E2, Canada
[5] Sir Mortimer B Davis Jewish Hosp, Dept Pharm, Montreal, PQ H3T 1E2, Canada
关键词
deep venous thrombosis; low-molecular-weight heparin; orthopedic surgery; thromboprophylaxis; venous thromboembolism;
D O I
10.1378/chest.128.5.3364
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: To evaluate risk factors for venous thromboembolism (VTE) despite thromboprophylaxis in major orthopedic surgery patients at a tertiary care hospital. Methods: Charts from consecutive patients who underwent total hip replacement (THR), total knee replacement (TKR), or hip fracture surgery (HFS) [hip pinning or hemiarthroplasty] from August 1, 1999, to April 30, 2000, at a large Canadian teaching hospital were abstracted using standardized case report forms. Data were collected on patient characteristics, surgical characteristics, and thromboprophylaxis regimen. Results of tests performed for suspected VTE were documented. Associations between characteristics of interest and objectively confirmed VTE were examined in multivariate analysis. Results: Over the study period, 310 patients underwent major orthopedic surgery and received standard thromboprophylaxis with either dalteparin or enoxaparin (mean duration of prophylaxis, 7 days). Of these, 34% underwent THR, 30% underwent TKR, and 36% underwent HFS. Of 83 suspected cases of VTE, 44 cases (7 proximal and 37 distal deep venous thrombosis [DVTI); 14% of study population) were confirmed with objective testing. Multivariate analyses revealed that knee surgery (odds ratio [OR], 4.8; 95% confidence interval [CI], 2.3 to 10.1) and type of low molecular weight heparin (LMWH) [enoxaparin (more protective): OR, 0.39; 95% CI, 0.20 to 0.80] independently predicted VTE. No patient characteristics (including previous VTE, malignancy, hormonal therapy, postoperative complications) were associated with VTE. Conclusion: Despite standard tbromboprophylaxis, symptomatic breakthrough VTE, primarily distal DVT, developed in 14% of patients undergoing major orthopedic surgery. Factors that independently predicted VTE in our population were TKR surgery and type of LMWH. TKR patients may warrant more aggressive postoperative physiotherapy and ambulation and adjunctive prophylactic measures such as pneumatic compression. Due to the heterogeneity of different LMWH compounds, direct comparison of the effectiveness of enoxaparin with dalteparin for orthopedic prophylaxis in prospective, randomized trials seems warranted.
引用
收藏
页码:3364 / 3371
页数:8
相关论文
共 24 条
[1]   Risk factors for venous thromboembolism [J].
Anderson, FA ;
Spencer, FA .
CIRCULATION, 2003, 107 :I9-I16
[2]   A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty [J].
Brookenthal, KR ;
Freedman, KB ;
Lotke, PA ;
Fitzgerald, RH ;
Lonner, JH .
JOURNAL OF ARTHROPLASTY, 2001, 16 (03) :293-300
[3]   Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty - Evaluation during hospitalization and three months after discharge [J].
Colwell, CW ;
Collis, DK ;
Paulson, R ;
McCutchen, JW ;
Bigler, GT ;
Lutz, S ;
Hardwick, ME .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1999, 81A (07) :932-940
[4]  
Cornelli U, 1999, SEMIN THROMB HEMOST, V25, P57
[5]   Late occurring clinical deep vein thrombosis in joint-operated patients [J].
Dahl, OE ;
Gudmundsen, TE ;
Haukeland, L .
ACTA ORTHOPAEDICA SCANDINAVICA, 2000, 71 (01) :47-50
[6]   Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement -: A meta-analysis of prospective studies investigating symptomatic outcomes [J].
Douketis, JD ;
Eikelboom, JW ;
Quinlan, DJ ;
Willan, AR ;
Crowther, MA .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (13) :1465-1471
[7]   Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a metaanalysis of the randomised trials [J].
Eikelboom, JW ;
Quinlan, DJ ;
Douketis, JD .
LANCET, 2001, 358 (9275) :9-15
[8]   Prevention of venous thromboembolism [J].
Geerts, WH ;
Heit, JA ;
Clagett, GP ;
Pineo, GF ;
Colwell, CW ;
Anderson, FA ;
Wheeler, HB .
CHEST, 2001, 119 (01) :132S-175S
[9]   Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement - A randomized, double-blind, placebo-controlled trial [J].
Heit, JA ;
Elliott, CG ;
Trowbridge, AA ;
Morrey, BF ;
Gent, M ;
Hirsh, J .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (11) :853-+
[10]   Relationship between deep venous thrombosis and the postthrombotic syndrome [J].
Kahn, SR ;
Ginsberg, JS .
ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (01) :17-26